Moderna’s Canadian manufacturing facility receives DEL from Health Canada

Moderna announced that its manufacturing facility in Laval, Quebec, has been granted a Drug Establishment License, DEL, from Health Canada. This certification affirms the facility’s compliance with rigorous safety and quality standards, authorizing it to produce drug substance. This key milestone enables Moderna’s Canadian manufacturing site to become fully operational, bringing the company closer to ensuring a reliable and onshore supply of mRNA vaccines within Canada. With the DEL in place, the facility will proceed with the final qualification process, positioning it to domestically manufacture a portfolio of mRNA vaccines against respiratory viruses beginning in 2025, including COVID-19 and, contingent on approval by Health Canada, respiratory syncytial virus, and seasonal influenza.